Incorrect password
evipedia.ai Suggest Edit

5-Amino-1MQ for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: 5-AMQ, 5A1MQ, 5-Amino-1-Methylquinolinium, 5-Amino-1-Methylquinolinium Iodide

Motivation

5-Amino-1MQ is a small synthetic molecule (often inaccurately marketed as a “peptide”) that selectively blocks a specific enzyme involved in cellular energy metabolism, helping preserve key cellular building blocks that support energy production, fat storage, and muscle function. It has drawn interest in the longevity community as a research-stage tool that targets a relatively novel metabolic pathway, with promising results in animal studies but no human clinical trial data.

Originally developed as a potential obesity therapeutic at the University of Texas Medical Branch, 5-Amino-1MQ has attracted attention in the longevity space because preclinical work suggests it can reduce body fat, improve insulin sensitivity, and enhance grip strength in aged mice — sometimes outperforming exercise alone. Compounding pharmacies and research-chemical suppliers have made it widely available despite the complete absence of human clinical trials.

This review examines the preclinical evidence for 5-Amino-1MQ across metabolic and muscle-aging endpoints, the known pharmacology, the gap between animal data and human use, and the practical considerations for those evaluating it as a research-stage longevity tool.

Benefits - Risks - Protocol - Conclusion

A curated selection of resources providing accessible overviews of 5-Amino-1MQ’s mechanism, preclinical evidence, and the broader case for NNMT (nicotinamide N-methyltransferase, a cytosolic enzyme that methylates nicotinamide and thereby links cellular energy balance with epigenetic regulation) inhibition as a longevity intervention.

No directly relevant content on 5-Amino-1MQ was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine. The compound remains outside the scope of mainstream longevity commentators, almost certainly because it lacks human clinical trial data and remains a research-stage molecule.

Grokipedia

5-Amino-1MQ

Grokipedia’s dedicated page on 5-Amino-1MQ summarizes its identity as a small-molecule NNMT inhibitor, the foundational 2018 preclinical findings on diet-induced obesity, and subsequent reports on metabolic and muscle-strength outcomes in aged mice.

Examine

Examine.com does not currently have a dedicated page for 5-Amino-1MQ.

ConsumerLab

ConsumerLab does not currently have a dedicated review page for 5-Amino-1MQ.

Systematic Reviews

No systematic reviews or meta-analyses for 5-Amino-1MQ were found on PubMed as of 05/02/2026.

Mechanism of Action

5-Amino-1MQ is a small quaternary ammonium molecule (a methylquinolinium scaffold with a primary amine at the 5-position) that acts as a selective, membrane-permeable inhibitor of NNMT (nicotinamide N-methyltransferase, a cytosolic enzyme that methylates nicotinamide and thereby links cellular energy balance with epigenetic regulation). The downstream consequences of NNMT inhibition include:

  • NAD+ preservation: NNMT normally converts nicotinamide (a precursor to NAD+, nicotinamide adenine dinucleotide, the central coenzyme of cellular energy production and DNA repair) into 1-methylnicotinamide, consuming a methyl group from SAM (S-adenosylmethionine, the universal methyl donor). By blocking NNMT, 5-Amino-1MQ preserves the nicotinamide pool available for NAD+ biosynthesis via the salvage pathway, raising intracellular NAD+
  • SAM conservation and methylation balance: Inhibition of NNMT preserves SAM, maintaining the cell’s methylation capacity for DNA methylation, histone modification, and polyamine biosynthesis. This is also expected to lower homocysteine, since less SAH (S-adenosylhomocysteine) is generated
  • Suppression of lipogenesis: In cultured adipocytes, 5-Amino-1MQ reduced intracellular 1-methylnicotinamide, increased NAD+ and SAM, and suppressed fat synthesis, shifting adipocyte metabolism away from lipid storage and toward oxidation
  • SIRT1 activation: Elevated NAD+ enables greater activity of SIRT1 (sirtuin 1, an NAD+-dependent deacetylase implicated in longevity, metabolic regulation, and stress resistance), which promotes fat oxidation through PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a master regulator of mitochondrial biogenesis)
  • AMPK and polyamine flux: NNMT inhibition has been associated with increased phosphorylation of AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes catabolic pathways when energy is low) and with upregulated polyamine flux through ODC (ornithine decarboxylase, the rate-limiting enzyme in polyamine synthesis) and SSAT (spermidine/spermine N1-acetyltransferase, an enzyme that drives polyamine catabolism) enzymes, which contribute to the increase in cellular energy expenditure observed after NNMT knockdown
  • Tissue-protective and anti-senescence effects: Recent preclinical work in kidney, cardiac, and skeletal-muscle tissues suggests that NNMT inhibition reduces senescence and fibrosis markers, indicating a broader role in cellular aging beyond pure metabolism

5-Amino-1MQ is highly selective: it does not inhibit structurally related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway. It is a small organic molecule, not a peptide, despite frequent mislabeling in consumer-facing wellness materials. Pharmacokinetics in rodents indicate good systemic exposure after oral and subcutaneous administration, with distribution to metabolically active tissues (adipose, muscle, liver). Reported rat oral bioavailability is approximately 38% with a terminal elimination half-life of roughly 6.9 hours after oral dosing; human pharmacokinetic data do not exist. As a quaternary ammonium small molecule, 5-Amino-1MQ undergoes minimal hepatic phase-I oxidative metabolism (no major CYP450 (cytochrome P450, a family of liver enzymes that oxidize and clear most prescription drugs) pathway has been characterized as primary); preclinical data indicate predominantly renal elimination of unchanged compound and conjugated forms.

Historical Context & Evolution

NNMT was first characterized as a hepatic enzyme involved in nicotinamide clearance and xenobiotic metabolism. Its broader relevance to systemic metabolism emerged in 2014, when a Beth Israel Deaconess / Harvard group reported in Nature that antisense knockdown of NNMT in white adipose tissue and liver protected mice against diet-induced obesity by augmenting cellular energy expenditure, raising NAD+ and SAM, and increasing polyamine flux. This established NNMT as a viable anti-obesity drug target.

A research group at the University of Texas Medical Branch, led by Stanley Watowich, subsequently developed a series of small-molecule NNMT inhibitors built on a methylquinolinium scaffold. Their 2018 Biochemical Pharmacology paper identified 5-Amino-1MQ as the lead compound, demonstrating membrane permeability, selectivity, and reductions in body weight, adiposity, and plasma cholesterol in diet-induced obese mice. The same group founded Ridgeline Therapeutics to advance NNMT inhibitors into the clinic. Conflict of interest note: A substantial share of the 5-Amino-1MQ literature originates from Watowich and Ridgeline Therapeutics employees; the company has a direct commercial interest in positive findings on NNMT inhibition.

Subsequent preclinical work expanded the rationale beyond obesity. A 2024 Scientific Reports study (Dimet-Wiley et al., authors employed by Ridgeline Therapeutics with collaborators from the University of Kentucky) reported that NNMT inhibition increased grip strength in aged mice more than intensive exercise, with additive effects when combined. A 2024 Aging Cell paper (Liang et al., independent group at Sichuan University, no Ridgeline affiliation) identified NNMT as a sarcopenia biomarker and showed that inhibition improved muscle mass and function in both naturally aged and accelerated-aging mouse models. A 2024 Diabetes, Obesity & Metabolism paper (Babula et al., authors employed by Ridgeline Therapeutics) reported expanded metabolic benefits of 5-Amino-1MQ, including improvements in hepatic steatosis and insulin sensitivity. More recent work (2025–2026) has extended the case to heart-failure-with-preserved-ejection-fraction, peripheral artery disease, diabetic kidney disease, and oncology applications, with mixed independent and Ridgeline-affiliated authorship.

Despite this growing preclinical literature, no human clinical trials of 5-Amino-1MQ have been registered as of May 2026. The compound’s adoption in the wellness and biohacking community accelerated around 2022–2023 as compounding pharmacies and research-chemical suppliers began offering it for off-label use, often inaccurately marketing it as a “peptide” despite it being a small quaternary ammonium organic molecule.

Expected Benefits

Low 🟩

Reduction in Body Weight and Adiposity

In diet-induced obese mice, daily systemic administration of 5-Amino-1MQ reduces body weight, white adipose tissue mass, and adipocyte size without altering food intake, while also lowering plasma total cholesterol. The 2024 Babula et al. study replicated and extended these findings, showing dose-dependent reductions in fat mass, attenuation of hepatic steatosis, and normalization of liver enzymes. The mechanism is consistent and internally coherent across studies, but no human data exist.

Magnitude: Approximately 30% reduction in adipocyte size and ~40% reduction in fat-pad volume in diet-induced obese mice; ~30% reduction in plasma total cholesterol; replicated dose-dependent body-weight reductions in independent rodent studies.

Improved Insulin Sensitivity and Glucose Regulation

NNMT knockdown and pharmacological inhibition consistently improve insulin sensitivity and glucose tolerance in rodent metabolic models. The 2024 Babula et al. study reported improved oral glucose tolerance and suppressed hyperinsulinemia in diet-induced obese mice treated with 5-Amino-1MQ. Elevated NNMT expression correlates with insulin resistance and type 2 diabetes in human observational data, and NNMT polymorphisms are associated with obesity susceptibility, but no interventional human evidence exists for 5-Amino-1MQ specifically.

Magnitude: Dose-dependent improvements in oral glucose tolerance and suppression of fasting hyperinsulinemia (chronically elevated insulin levels) in diet-induced obese mice; not quantified in humans.

Improved Muscle Strength and Function in Aging

The 2024 Dimet-Wiley et al. study reported that aged (22–24-month-old) mice treated with an NNMT inhibitor for two months developed approximately 40% greater grip strength than sedentary controls, exceeding the ~20% benefit of intensive exercise alone. Combined NNMT inhibition plus exercise produced an additive ~60% increase. A separate 2024 paper by Liang et al. confirmed that NNMT inhibition improved grip strength and lean mass in both D-galactose-accelerated-aging and naturally aged mouse models. All evidence is preclinical.

Magnitude: ~40% grip-strength increase over sedentary controls; ~60% increase when combined with exercise in aged mice (Dimet-Wiley et al. 2024).

Enhanced Muscle Stem Cell Activation and Regeneration

Preclinical work has shown that NNMT inhibition activates senescent muscle stem cells in aged mice, increasing their proliferation and differentiation, and produces larger regenerating muscle fibers and greater fiber cross-sectional area after injury. These data suggest potential utility for recovery from age-related muscle decline and injury, but remain limited to mouse models.

Magnitude: Approximately 2-fold greater cross-sectional area of regenerating fibers versus controls after muscle injury in aged mice.

Attenuation of Hepatic Steatosis

In diet-induced obese mice, 5-Amino-1MQ reduced liver weight, hepatic triglyceride levels, and macrophage infiltration, and normalized circulating ALT (alanine aminotransferase, a liver enzyme) and AST (aspartate aminotransferase, a liver and muscle enzyme). The 2025 review by Zhang et al. summarizes the broader mechanistic case for NNMT inhibition in non-alcoholic fatty liver disease, but human evidence is absent.

Magnitude: Significant reductions in liver weight, hepatic triglycerides, and circulating liver enzymes in diet-induced obese mice; magnitudes not standardized for human translation.

Speculative 🟨

Cardiovascular and Cardiometabolic Protection

Preclinical work in 2025 (Li et al.) reported that an NNMT inhibitor improved cardiac function (global longitudinal strain), reduced left-ventricular hypertrophy and fibrosis, and lowered pro-inflammatory and pro-fibrotic gene expression in a heart-failure-with-preserved-ejection-fraction mouse model. Reviews position NNMT as an emerging cardiovascular target via NAD+/SAM regulation and homocysteine-lowering effects. Human cardiovascular outcomes data do not exist.

Anti-Senescence Effects in Kidney and Vascular Tissue

A 2026 Cell Reports paper (Chanvillard et al.) identified NNMT as a mediator of tubular senescence and fibrosis in early chronic kidney disease, showing that selective NNMT inhibition was protective in human kidney organoids and rodent models. A 2025 Physiological Reports paper (Dong et al.) reported improved muscle strength and reduced necrosis in a peripheral-artery-disease model. These point toward broader longevity applications but are early-stage preclinical findings.

Anti-Cancer Activity (Context-Dependent)

NNMT is overexpressed in many solid tumors, and meta-analyses associate high NNMT expression with poorer survival across cancer types. A 2025 Nature paper (Heide et al.) reported that NNMT inhibition in cancer-associated fibroblasts restored antitumor immunity in ovarian, breast, and colon mouse models. A 2024 Journal for ImmunoTherapy of Cancer paper used 5-Amino-1MQ to enhance anti-PD-L1 (programmed death-ligand 1, an immune checkpoint protein targeted by some cancer therapies) efficacy in bladder-cancer mouse models. These findings are tumor-microenvironment-specific and have not been translated to humans, and the compound’s effects on SIRT1 and proliferation pathways are context-dependent — meaning a clear net benefit or harm in active malignancy cannot yet be claimed.

Favorable Gut Microbiome Modulation

A single mouse study reported that diet-induced obese mice receiving 5-Amino-1MQ alongside a low-fat diet developed a distinct gut microbiome signature (decreased Erysipelatoclostridium, increased Lactobacillus) compared with diet change alone. The biological significance of this shift in humans is unknown.

Benefit-Modifying Factors

  • NNMT gene polymorphisms: Single-nucleotide variants in the NNMT gene (e.g., rs10891644 and rs694539, regulatory-region variants that influence NNMT gene expression and enzyme activity in adipose and liver tissue) are associated with differences in body fat composition, obesity susceptibility, and metabolic syndrome traits. Individuals with higher baseline NNMT expression or activity may theoretically derive greater benefit from inhibition, though this is untested in humans
  • Baseline metabolic status: Preclinical evidence suggests effects are most pronounced in the context of metabolic dysfunction (obesity, insulin resistance, hepatic steatosis). Lean, metabolically healthy individuals with normal NNMT expression may experience smaller effects
  • Sex-based differences: Most preclinical metabolic studies were conducted in male mice, while the 2025 cardiac study used aged female mice. Whether sex-based differences in NNMT expression or response to inhibition exist in humans is unknown
  • Pre-existing health conditions: Individuals with obesity, metabolic syndrome, insulin resistance, or sarcopenia may theoretically be better candidates because NNMT is upregulated in these conditions. The presence of active cancer warrants extra caution given context-dependent effects
  • Age: NNMT expression rises with age in skeletal muscle and is a dominant component of the gene-expression signature for sarcopenia. Older individuals may potentially gain more from NNMT inhibition for muscle-related outcomes, although they also face greater uncertainty around long-term safety

Potential Risks & Side Effects

Low 🟥

Mild Gastrointestinal Discomfort

Anecdotal reports from individuals taking oral 5-Amino-1MQ describe mild nausea, abdominal discomfort, and transient digestive changes, particularly during the first one to two weeks of use. These are self-reported and not documented in controlled human studies. Preclinical mouse studies did not report gastrointestinal adverse events but did not specifically assess them.

Magnitude: Not quantified in available studies.

Headache and Fatigue During Initial Use

Self-reported user accounts describe transient headaches and fatigue during the first several days, often attributed to metabolic adjustment. There is no preclinical or clinical confirmation or quantification of this signal.

Magnitude: Not quantified in available studies.

Sleep Disruption with Late-Day Dosing

User reports suggest that taking 5-Amino-1MQ later in the day may interfere with sleep onset, plausibly tied to elevated NAD+ and increased metabolic activity. No controlled data exist.

Magnitude: Not quantified in available studies.

Speculative 🟨

Unknown Long-Term Safety in Humans

No human clinical trials of any duration have been conducted. The entire safety profile is extrapolated from short-term rodent studies (typically 4 weeks to a few months) and uncontrolled anecdotal reports. Long-term consequences of sustained NNMT inhibition in humans — including effects on methyl-group balance, epigenetic regulation, and tissue-specific responses — are unknown.

Perturbation of Cellular Methylation Balance

NNMT inhibition preserves SAM, which could shift global methylation balance. While this is metabolically favorable in adipose tissue and likely beneficial for homocysteine, chronic perturbation of the methyl-donor pool could in theory have unintended epigenetic consequences. This remains a theoretical concern not observed in published preclinical work.

Context-Dependent Effects in Cancer Biology

NNMT inhibition has shown anti-tumor effects in several preclinical cancer models, particularly via the tumor microenvironment, but SIRT1 modulation and effects on cellular proliferation can be context-dependent. Individuals with active malignancies should treat this as a complex, undefined risk rather than a clear benefit.

Uncertain Effects on Liver and Kidney Function

NNMT is highly expressed in the liver and plays a physiological role in nicotinamide clearance and xenobiotic metabolism. While preclinical data suggest hepatoprotection in steatosis models, the effects of chronic NNMT inhibition on hepatic and renal function in humans, especially in individuals with pre-existing liver or kidney disease, have not been studied.

Drug Identity and Quality Risks

Because 5-Amino-1MQ is sold primarily through compounding pharmacies and research-chemical suppliers without standardized regulatory oversight, batch-to-batch purity, identity, and contamination risks are themselves a safety concern that overlays any pharmacological risks.

Risk-Modifying Factors

  • NNMT gene polymorphisms: Variants influencing NNMT expression or activity could plausibly influence susceptibility to side effects from NNMT inhibition. No pharmacogenomic data exist for this compound
  • Baseline metabolic status: Lean, metabolically healthy individuals with low baseline NNMT may experience different risk profiles than those with elevated NNMT, though this has not been formally tested
  • Sex-based differences: Potential sex-based differences in NNMT expression and inhibition response are not characterized in humans, and most preclinical metabolic data are from male mice
  • Pre-existing liver or kidney disease: Given NNMT’s physiological role in hepatic metabolism and the absence of safety data in hepatic or renal impairment, individuals with these conditions face heightened uncertainty
  • Age: While older adults are the target population for muscle-related benefits, they may also be more vulnerable to unknown adverse effects due to polypharmacy, reduced metabolic reserve, and comorbidity

Key Interactions & Contraindications

  • Diabetes medications (metformin, sulfonylureas such as glipizide and glyburide, insulin): 5-Amino-1MQ may potentiate hypoglycemic effects through improved insulin sensitivity in preclinical models. Caution; close blood-glucose monitoring is warranted, and dose adjustment of the antidiabetic agent may be required
  • SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, e.g., empagliflozin, dapagliflozin): A 2025 preclinical study reported synergistic renal-protective effects with combined NNMT and SGLT2 inhibition, but also additive metabolic effects. Monitor; theoretical additive glucose-lowering and diuretic effects
  • Antihypertensives (e.g., losartan, lisinopril, amlodipine): Caution; NNMT gene variants associate with hypertension and NNMT inhibition may modestly lower blood pressure. Monitor for additive effects, particularly with multi-agent regimens
  • NAD+ precursors (NMN, NR, niacin): 5-Amino-1MQ raises intracellular NAD+ by preserving the nicotinamide pool. Caution; combining with exogenous NAD+ precursors may produce supraphysiological NAD+ elevation, with potential clinical consequences including flushing (with niacin), gastrointestinal upset, and theoretical promotion of cellular proliferation in tissues with pre-malignant changes
  • Methyl donors (SAMe, methylated folate, methylcobalamin): NNMT inhibition preserves SAM. Monitor; co-administration with high-dose methyl donors may produce hypermethylation-associated effects such as anxiety, insomnia, headache, or altered mood, and could perturb downstream methylation-dependent pathways (e.g., catecholamine and homocysteine metabolism)
  • Hepatically metabolized OTC analgesics (acetaminophen, NSAIDs such as ibuprofen and naproxen): Caution; NNMT contributes to hepatic xenobiotic metabolism. Concurrent use of acetaminophen, primarily cleared by the liver, warrants awareness, particularly during prolonged use or higher doses
  • CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice): CYP3A4 is a major liver enzyme that metabolizes a large share of common drugs. No human pharmacokinetic interaction data exist. Monitor; theoretical concern given that any oral compound interacting with hepatic biology may have altered clearance with strong CYP3A4 inhibitors
  • Stimulants (caffeine at high doses, ephedrine, thermogenic blends): Anecdotal reports describe increased metabolic rate and energy with 5-Amino-1MQ. Caution; theoretical additive stimulatory effect

Populations who should avoid this intervention:

  • Pregnant or breastfeeding women (no safety data; absolute contraindication)
  • Individuals with active cancer (context-dependent SIRT1 and proliferation effects; absolute contraindication outside formal oncology supervision)
  • Individuals with severe liver disease (Child-Pugh Class B–C) or advanced kidney disease (eGFR (estimated glomerular filtration rate, a kidney function marker) <45 mL/min/1.73m²) — caution to avoidance, given NNMT’s hepatic role and the absence of dose-adjustment data
  • Individuals under 18 years of age (no pediatric safety data; absolute contraindication)
  • Competitive athletes subject to anti-doping testing — prohibited under WADA (World Anti-Doping Agency) Category S0 (Non-Approved Substances) at all times

Risk Mitigation Strategies

  • Conservative starting dose: Begin at 50 mg orally once daily for 1–2 weeks to assess tolerance and surface gastrointestinal, headache, or sleep-related side effects before considering escalation. Mitigates: acute tolerability issues
  • Morning dosing: Take the daily dose in the morning rather than evening to limit potential interference with sleep onset attributed to elevated NAD+ and metabolic activity. Mitigates: sleep disruption
  • Defined cycling protocol: Use 8–12 weeks on followed by 4–6 weeks off rather than continuous indefinite use, to limit the duration of uncharacterized chronic NNMT inhibition. Mitigates: unknown long-term safety
  • Baseline and periodic laboratory monitoring: Obtain baseline and every-3-months ALT, AST, creatinine, eGFR (estimated glomerular filtration rate, a kidney function marker), fasting glucose, fasting insulin, HbA1c (glycated hemoglobin, a 3-month average blood-sugar marker), and lipid panel to surface hepatic, renal, and metabolic shifts early. Mitigates: undetected hepatic, renal, or metabolic adverse effects
  • Tighter glucose monitoring with antidiabetic agents: Individuals taking metformin, sulfonylureas, or insulin should monitor fasting and postprandial glucose more frequently during the first 4–6 weeks of 5-Amino-1MQ use. Mitigates: hypoglycemia from additive insulin sensitization
  • Source verification with certificate of analysis: Source only from compounding pharmacies or suppliers that provide batch-specific certificates of analysis confirming ≥98% purity by HPLC (high-performance liquid chromatography) or LC-MS/MS (liquid chromatography-tandem mass spectrometry). Mitigates: identity, purity, and contamination risks inherent to unregulated supply chains
  • Healthcare provider involvement: Particularly relevant for individuals on prescription medications, with comorbidities, or pursuing combined NAD+ precursor or methyl-donor regimens, given the absence of formal drug-interaction data. Mitigates: interaction-related adverse events
  • Avoid combined methyl-donor stacking initially: Defer or limit concurrent high-dose SAMe, methylated folate, or methylcobalamin during the first cycle so that any methylation-related effects can be attributed and titrated. Mitigates: unintended methylation-balance perturbation

Therapeutic Protocol

The following protocol is derived from community use, compounding-pharmacy guidance (including widely cited regimens from Tailor Made Compounding and similar specialty compounders that have offered 5-Amino-1MQ since approximately 2022–2023), and extrapolation from preclinical dosing in the Watowich group’s work at the University of Texas Medical Branch. No human clinical trial has established a safe or effective human dose. There is no single “leading practitioner” body of work in the conventional sense; the most data-driven approach starts low and uses defined cycles.

  • Starting dose: 50 mg orally once daily for 1–2 weeks to assess tolerance
  • Standard dose: 100 mg orally once daily, the most commonly reported community dose
  • Upper community range: 150 mg orally once daily, used by some practitioners for higher-body-weight individuals or more aggressive metabolic targets
  • Timing: Morning, with or without food. Late-day dosing has been associated with sleep disruption in anecdotal reports
  • Cycle length: 8–12 weeks on, then 4–6 weeks off. A more conservative pattern of 6 weeks on, 3 weeks off is also used
  • Alternative routes: Subcutaneous injection is offered by some compounding sources but has no clear advantage over oral dosing given the compound’s reasonable oral bioavailability in rodents and is rarely used outside specialized clinics

Half-life and dosing frequency: In rat pharmacokinetic studies, 5-Amino-1MQ showed a terminal elimination half-life of approximately 3.8 hours after intravenous dosing and ~6.9 hours after oral dosing, with oral bioavailability of ~38%. These values cannot be directly translated to humans, but a single daily oral dose is the standard practice.

Single vs. split dosing: Once-daily morning dosing is the established community practice. Split dosing is not commonly used and could increase the risk of late-day sleep interference.

  • Genetic polymorphisms: NNMT variants (e.g., rs10891644, rs694539) may influence response, but no pharmacogenomic testing protocols exist for this compound, and commercial SNP (single nucleotide polymorphism, a single-letter DNA variation) panels for these markers are not standard
  • Sex-based considerations: Most preclinical metabolic data come from male mice; some recent cardiac data come from aged female mice. Whether women respond differently to NNMT inhibition is unknown, supporting conservative dosing for all users
  • Age-related considerations: Preclinical muscle-aging data come from 22–24-month-old mice (roughly equivalent to ~65–70 human years), suggesting older adults may be the most clearly motivated population for muscle-related goals while also facing greater uncertainty around long-term safety
  • Baseline biomarkers: Individuals with elevated NNMT expression — typically correlating with obesity, insulin resistance, hepatic steatosis, and aging — may theoretically respond more robustly. NNMT is not measured in standard clinical practice
  • Pre-existing conditions: Individuals with diabetes should monitor glucose more closely; those with liver or kidney disease should avoid use or proceed with extreme caution given NNMT’s hepatic role; those with active malignancy should not use outside formal oncology oversight

Discontinuation & Cycling

  • Duration of use: Given the absence of human safety data, 5-Amino-1MQ is not established as either a short-term or lifelong intervention. The community consensus favors time-limited, repeated cycles
  • Withdrawal effects: No withdrawal effects have been reported in preclinical studies or in anecdotal user accounts. Endogenous NNMT activity is expected to resume once the inhibitor clears the system
  • Tapering protocol: No tapering is needed. Abrupt discontinuation is the standard practice, and NNMT activity is expected to return to baseline as the compound clears
  • Cycling rationale: Cycling (8–12 weeks on, 4–6 weeks off, or 6 weeks on, 3 weeks off) is the predominant community practice. Stated goals are to limit the duration of uncharacterized chronic NNMT inhibition, allow reassessment of ongoing benefit, and potentially prevent any adaptive upregulation of NNMT expression or compensatory metabolic changes

Sourcing and Quality

  • Regulatory status: 5-Amino-1MQ is not FDA (Food and Drug Administration)-approved for any indication. It is not a dietary supplement, not a controlled substance, and not a pharmaceutical drug. It is sold as a research compound or via compounding pharmacies
  • Form factor: Most commonly available as oral capsules (typically 50 mg). Some sources offer subcutaneous injectable formulations; oral remains the standard route given demonstrated oral bioavailability in animals
  • Purity considerations: Product quality varies meaningfully between suppliers. Reputable sourcing requires a batch-specific certificate of analysis showing ≥98% purity by HPLC (high-performance liquid chromatography) or LC-MS/MS (liquid chromatography-tandem mass spectrometry), and ideally heavy-metal and residual-solvent testing
  • Reputable channels: Compounding pharmacies operating under state-board oversight that provide certificates of analysis are preferred over unregulated online retailers. Examples of compounding pharmacies that have offered 5-Amino-1MQ in the U.S. specialty market include Tailor Made Compounding (Lexington, KY) and Empower Pharmacy (Houston, TX); availability changes over time and prescriber requirements vary by state. A licensed healthcare provider is typically required to obtain compounded oral capsules
  • Genotoxicity testing: Available genotoxicity data on 5-Amino-1MQ in standard bacterial and mammalian cell assays did not show genotoxic activity. These data are limited and not equivalent to a full regulatory toxicology program
  • Identity verification: Because the compound is frequently and incorrectly marketed as a “peptide,” product authentication is meaningful: the authentic compound is the small-molecule quaternary ammonium form (5-amino-1-methylquinolinium iodide), distinct from any misidentified peptide product

Practical Considerations

  • Time to effect: Anecdotal reports describe noticeable changes in energy and metabolic rate within 1–2 weeks, with body-composition changes typically apparent within 4–8 weeks. Preclinical studies in mice showed measurable weight and adiposity changes within ~11 days of treatment
  • Common pitfalls: Treating 5-Amino-1MQ as an established therapeutic rather than a research-stage compound; sourcing without certificates of analysis; combining with multiple metabolic supplements without monitoring; dosing late in the day and experiencing sleep disruption; expecting dramatic fat loss without diet and exercise — preclinical effects were most pronounced when paired with dietary improvements
  • Regulatory status: 5-Amino-1MQ is an unapproved new drug in the United States and most jurisdictions. The FDA has not evaluated it for safety or efficacy and it cannot be legally marketed as a dietary supplement or medicine. It is prohibited at all times in competitive sport under WADA Category S0 (Non-Approved Substances)
  • Cost and accessibility: Typically priced between $60 and $150 for a 30–60-day oral supply depending on dose and source. Available through compounding pharmacies, often requiring a healthcare provider’s order, and through some research-chemical suppliers. Accessibility varies by jurisdiction and is more constrained in markets with active enforcement against unapproved compounds

Interaction with Foundational Habits

  • Sleep: Anecdotal reports suggest taking 5-Amino-1MQ later in the day may interfere with sleep onset, plausibly via increased metabolic activity and elevated NAD+ levels affecting circadian-related pathways. The interaction is best characterized as indirect/potentiating of wakefulness; mechanistically, NAD+ levels naturally fluctuate with circadian rhythm, and morning dosing aligns with the upswing. Reported community practice: morning dosing is favored and late-evening administration is generally avoided
  • Nutrition: Preclinical evidence shows the most pronounced effects on weight and adiposity when 5-Amino-1MQ is paired with dietary improvement (e.g., switching from high-fat to low-fat or otherwise improved diet). The interaction is direct/potentiating with diet quality. The compound does not appear to suppress appetite or change food intake in animal data, so it is unlikely to overcome the metabolic consequences of a persistently poor diet. Reported community practice: pairing with a structured nutrition plan rather than reliance on the compound alone
  • Exercise: The 2024 Dimet-Wiley et al. study provides the strongest evidence that NNMT inhibition and intensive exercise produce additive improvements in grip strength in aged mice (60% combined vs. 40% NNMT-inhibitor-alone vs. 20% exercise-alone). The interaction is direct/potentiating, with distinct molecular signatures from each intervention plus a unique combined signature. Reported community practice: combination with resistance and aerobic training, particularly for muscle-aging goals
  • Stress management: No direct human or rodent data describe interaction of 5-Amino-1MQ with cortisol or the stress response. Mechanistically, indirect SIRT1 activation via NAD+ elevation has been associated with improved stress resilience in preclinical models. The interaction is best characterized as indirect and unproven in humans. Reported community practice: stress-management practices remain a foundation independent of any pharmacological adjuncts

Monitoring Protocol & Defining Success

Baseline labs should be obtained before starting 5-Amino-1MQ, with follow-up testing at 4–6 weeks after initiation, again at the end of each 8–12-week cycle, and at least every 6–12 months during long-term cycled use. Given the absence of established monitoring guidelines, the following protocol is based on the compound’s known mechanism and theoretical risk profile.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 72–85 mg/dL Detects insulin-sensitizing effects Conventional range 65–99 mg/dL; fasting 8–12 hours
Fasting insulin 2–5 µIU/mL Tracks insulin-sensitivity changes Conventional range 2.6–24.9 µIU/mL; pair with glucose for HOMA-IR (homeostatic model assessment of insulin resistance) calculation
HbA1c 4.8–5.2% Long-term glucose control HbA1c = glycated hemoglobin, a 3-month average blood-sugar marker; conventional range below 5.7%; reflects 2–3 months of glucose exposure
Lipid panel (total cholesterol, LDL, HDL, triglycerides) Total cholesterol 160–200 mg/dL; LDL below 100 mg/dL; HDL above 60 mg/dL; triglycerides below 80 mg/dL Tracks cholesterol-lowering effects observed in preclinical data LDL = low-density lipoprotein; HDL = high-density lipoprotein; conventional triglycerides below 150 mg/dL; fasting recommended
ALT 10–26 U/L (men); 10–20 U/L (women) Monitors liver safety given NNMT’s hepatic role ALT = alanine aminotransferase, a liver enzyme; conventional range 7–56 U/L
AST 10–26 U/L Monitors liver and muscle tissue integrity AST = aspartate aminotransferase, a liver and muscle enzyme; conventional range 10–40 U/L; can rise after intense exercise
Creatinine 0.7–1.1 mg/dL (men); 0.6–0.9 mg/dL (women) Monitors kidney function Pair with eGFR; affected by muscle mass
eGFR Above 90 mL/min/1.73m² Assesses overall kidney filtration capacity eGFR = estimated glomerular filtration rate, a kidney function marker; below 60 indicates moderate kidney impairment
Homocysteine 5–7 µmol/L Tracks methylation-balance shifts (NNMT inhibition preserves SAM and may lower homocysteine) Conventional range below 15 µmol/L; fasting morning sample preferred
Body composition (DEXA preferred; bioimpedance acceptable) Improving lean-mass-to-fat-mass ratio Tracks the primary expected outcome DEXA = dual-energy X-ray absorptiometry; measure at baseline and end of each cycle
Grip strength Maintenance or age-adjusted improvement Functional measure of muscle-strength benefit Use a calibrated dynamometer; test dominant hand, best of three attempts

Qualitative markers to track:

  • Energy levels through the day
  • Sleep quality and onset latency, especially when dose timing changes
  • Exercise recovery time and perceived exertion
  • Appetite and satiety patterns
  • Gastrointestinal comfort
  • Cognitive clarity and mood

Emerging Research

The 5-Amino-1MQ research base remains entirely preclinical, with the most active development through Ridgeline Therapeutics and academic collaborators. As of May 2026, no clinical trials of 5-Amino-1MQ or any other small-molecule NNMT inhibitor have been registered on ClinicalTrials.gov. Several emerging research directions could meaningfully strengthen — or weaken — the case for NNMT inhibition as a longevity-relevant intervention.

Conclusion

5-Amino-1MQ represents a scientifically interesting approach to metabolic and muscle aging through a novel mechanism — selective blockade of an enzyme that depletes the cellular pool of an energy coenzyme and the universal methyl donor. The preclinical evidence is consistent: across multiple research groups, the compound reduces adiposity and liver fat, improves insulin sensitivity, lowers plasma cholesterol, and enhances grip strength and muscle regeneration in aged mice, sometimes additively with exercise. Selectivity, oral availability, and a benign short-term rodent safety profile are attractive features.

The current evidence base has a fundamental limitation: it is entirely preclinical, and a substantial share of the published research originates from the University of Texas Medical Branch group and Ridgeline Therapeutics, the company holding a direct commercial interest in this compound. No human trials have been conducted, no safe or effective human dose has been established, and long-term consequences in humans are unknown. Marketing has outpaced the science, including widespread mislabeling as a “peptide.” Anti-doping authorities prohibit it, and product quality varies across the unregulated supply chain.

The evidence supports biological plausibility and preclinical promise — not proven human benefit. The risk profile appears favorable in limited animal data and uncontrolled anecdotal reports, while the absence of controlled human safety data leaves current use under substantial uncertainty, and individuals with cancer, liver or kidney disease, pregnancy, or pediatric status face heightened risk. The wide gap between animal data and any human experience defines the compound’s current evidence position.

Top - Benefits - Risks - Protocol